Veterinary and comparative oncology最新文献

{"title":"Evaluating the Impact of Elective Nodal Irradiation for Dogs With Oral Malignant Melanoma Undergoing Hypofractionated Radiotherapy.","authors":"Patricia Gualtieri, Lisa Group, David M Ruslander, Michael W Nolan, Mary-Keara Boss","doi":"10.1111/vco.70005","DOIUrl":"https://doi.org/10.1111/vco.70005","url":null,"abstract":"<p><p>Hypofractionated radiotherapy (hRT) is often used to treat dogs with oral malignant melanoma (OMM); however, there is no consensus as to whether clinically uninvolved regional lymph nodes should be prophylactically irradiated. The objective of this retrospective study is to compare outcomes for dogs with OMM treated with hRT+/- elective nodal irradiation (ENI). Dogs with nonmetastatic OMM undergoing hRT+/- ENI with a prescription of ≥ 30 Gy were included. Survival statistics were evaluated with Kaplan-Meier curves and log-rank testing. Univariable and multivariable Cox proportional hazard models were used to assess how survival was impacted by the use of ENI, WHO T-stage, mitotic count, RT technique, and use of Oncept melanoma vaccine. Data from four institutions and 100 dogs (80 with ENI and 20 without) were included. In the ENI group, nodal and distant metastases were documented in 4 and 30 dogs, respectively. In the non-ENI group, nodal and distant metastases were documented in 6 and 4 dogs, respectively. There was no significant difference in the 1-year nodal or distant progression-free intervals (p = 0.174, and 0.563, respectively). The only variable maintaining significance on multivariable analysis was T-stage (overall progression-free survival, HR 1.393, p = 0.006; overall survival time, HR 1.426, p = 0.005; distant progression-free interval, HR 1.521, p = 0.033). ENI did not measurably alter the oncologic outcomes in this study population. Results should be interpreted cautiously given the lack of standardised staging/restaging and the heterogenous nature of this clinical population. Future investigations are needed to clarify the role of ENI in the treatment of canine OMM.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose and Duration of Upfront Steroid Administration Have no Prognostic Impact in Dogs With Multicentric Diffuse Large B-Cell Lymphoma.","authors":"Ilaria Maga, Silvia Sabattini, Valeria Martini, Fulvio Riondato, Luca Aresu, Laura Marconato","doi":"10.1111/vco.70004","DOIUrl":"https://doi.org/10.1111/vco.70004","url":null,"abstract":"<p><p>Steroids provide rapid clinical improvement in dogs with multicentric diffuse large B-cell lymphoma (DLBCL). However, their use before chemotherapy can induce chemoresistance and compromise diagnostic yield due to increased apoptotic cells. This retrospective study assessed the impact of steroid dose and duration on flow cytometry (FC) diagnostic yield and clinical outcomes in dogs with DLBCL subsequently treated with chemotherapy. Of 273 dogs diagnosed with DLBCL between January 2014 and March 2024, 67 (24.5%) received steroids before treatment (median dose: 1 mg/kg, range: 0.5-3 mg/kg; median duration 8 days, range: 1-1080 days). In 94.0% of cases, steroids were administered for lymphoma management. All dogs received CHOP-based chemotherapy, and 38 (56.7%) also received immunotherapy. Median time to progression (TTP) and lymphoma-specific survival (LSS) were 143 days (95% CI: 111-175) and 196 days (95% CI: 152-240), respectively. Steroid dose, duration, and cumulative dose had no significant impact on TTP or LSS. However, the addition of immunotherapy was associated with longer LSS (p = 0.023). FC diagnostic yield was lower in steroid-treated dogs compared to 67 non-pre-treated dogs (p = 0.042). However, within the pre-treated group, neither dose nor duration impacted diagnostic yield (p > 0.05). In addition, TTP (p = 0.003) and LSS (p < 0.001) were significantly longer in non-pre-treated dogs compared to steroid-treated dogs. These findings suggest that the detrimental effects of upfront steroids are independent of dose or duration. Given their potential to compromise diagnosis and treatment outcomes, corticosteroids should be used with caution and reserved for cases where clinical benefits clearly outweigh the risks.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of a 4.3 Gy × 10-Fraction Volumetric Modulated Arc Therapy Protocol for Canine Prostatic Carcinoma: A Normal Tissue Complication Probability Study.","authors":"MyoungHun Kim, InSeong Jeong, KiDong Eom, JaeHwan Kim","doi":"10.1111/vco.70002","DOIUrl":"https://doi.org/10.1111/vco.70002","url":null,"abstract":"<p><p>The fraction size in canine pelvic tumours has traditionally been limited to minimisze radiation toxicity. However, advancements in precision radiotherapy techniques have enabled the use of larger fraction sizes, thereby facilitating a reduction in the overall treatment course. This study assessed the radiation toxicity risks of a 10-fraction radiation protocol for canine prostatic carcinoma by calculating normal tissue complication probabilities (NTCPs). Computed tomography data from 22 dogs with prostatic carcinoma were analysed. The new protocol was designed to deliver 43 Gy in 10 fractions over 2 weeks (Monday-Friday), with a biologically effective dose similar to that of standard protocols. Compared to the standard 20-fraction protocol, the 10-fraction protocol demonstrated comparable toxicity risks in most organs except for some rectal endpoints and the urethra, while also offering advantages in treatment time and patient convenience. Nevertheless, under the 10-fraction protocol, the relatively high NTCPs for late rectal toxicities and the identification of patients at high risk of toxicity support the recognition of the rectum as a primary organ at risk in hypofractionated radiotherapy. Rectal toxicity risks were higher in patients with trigonal invasion, dorsal rectal displacement or rectal narrowing. Higher tumour length/L6 height and maximal tumour diameter/L6 height ratios were associated with increased rectal NTCPs. Relative tumour size indices effectively predicted patients at high risk for rectal toxicity. Cut-off values were identified for acute rectal toxicity (Grade ≥ 2; tumour height/pelvic inlet ratio: 0.62), rectal bleeding (Grade 2; tumour height/L6 height: 4.03) and proctitis (Grade 2; maximal tumour diameter/pelvic inlet ratio: 0.82). These findings highlight the importance of relative tumour size indices as predictive markers for rectal toxicity risk in the 10-fraction protocol. The results suggest that the 10-fraction, 43 Gy protocol may be safely applied when tumour size remains below specific thresholds.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144508598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polarisation Sensitive Optical Coherence Tomography Image Characteristics for Gastrointestinal Tumours and Normal Tissues at Surgical Margins in Dogs.","authors":"Hannah L Weaver, Gabrielle S Fontes, Yi-Fan Shen, Ryan Jennings, Janis M Lapsley, Laura E Selmic","doi":"10.1111/vco.70001","DOIUrl":"10.1111/vco.70001","url":null,"abstract":"<p><p>The treatment of choice for canine alimentary tract neoplasms is surgical excision, but it can sometimes be difficult to achieve wide margins due to neoplasm location, size, or distribution. Optical coherence tomography (OCT) is a rapid, noninvasive imaging modality that uses light to characterise tissue microstructure to allow identification of different tissue types. Spectral domain (SD)-OCT allows for differentiation based on the total light intensity reflected from the tissue. Polarisation sensitive (PS)-OCT detects the polarisation state of light reflected by the tissues. The polarisation properties are phase retardation, degree of polarisation uniformity (DOPU), and optical axis. Our objective was to qualitatively characterise different tissues at the excision sites of alimentary tract neoplasms using OCT. Oral, liver, and other alimentary tumours including stomach, intestine, and pancreas were imaged. Samples were then fixed in formalin, paraffin embedded and stained with haematoxylin and eosin. OCT images and histology slides were compared, and the tissues were qualitatively described by a single investigator. We hypothesized that PS-OCT imaging would provide distinguishing characteristics of tissue appearances that could be used in the future to train observers or artificial intelligence to identify incomplete margins. Our results showed that alimentary tract tumours have disorganised microstructures on SD-OCT and PS-OCT DOPU, and PS-OCT phase retardation and optical axis values that differ from normal tissues. Thus, these characteristics can be used to differentiate neoplastic and normal tissues at surgical margins.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SHINE - Validation of Near Infrared Fluorescence Lymphography Against Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Dogs With Mast Cell Tumours.","authors":"L E Chiti, P Beer, S M Ohlerth, S Hartnack, M C Nolff","doi":"10.1111/vco.13058","DOIUrl":"10.1111/vco.13058","url":null,"abstract":"<p><p>Lymphoscintigraphy is the gold standard among sentinel lymph node (SLN) mapping techniques. Unfortunately, lymphoscintigraphy is not readily accessible, leading to the need for validation of alternative techniques. The aim of this study is to compare near-infrared fluorescence lymphography (NIRF-L) with lymphoscintigraphy for SLN resection in MCT and assess the impact of intraoperative NIRF guidance. Forty-eight dogs with 60 MCT were included in this prospective, blinded, randomised controlled trial. Dogs underwent preoperative lymphoscintigraphy and were then randomised into two groups: in the treatment group (n = 30) intraoperative NIRF-L was performed; in the control group (n = 30) no intraoperative guidance was implemented. Detection rate, concordance, sensitivity, and negative predictive values were recorded for NIRF-L and lymphoscintigraphy. Surgical time and length of surgical incision were compared between treatment and control groups with the Wilcoxon test (5% significance). Detection rate was 100% for NIRF-L and 98% for lymphoscintigraphy. Discordance occurred in one case. Sensitivity of NIRF-L was 93.7% (95% C.I. 74.3%-99.3%) and negative predictive value ranged between 91.1% and 98.6% with a prevalence of nodal metastases of 61% and 18%. Based on the overlapping of the confidence intervals, NIRF-L was not statistically different to lymphoscintigraphy for sensitivity. Lymphadenectomy was unsuccessful in 4/30 (13%) cases in the control group. Surgical time and incision were significantly shorter in the treatment group (p < 0.001; p = 0.001). Based on our results, NIRF-L is a valid alternative to lymphoscintigraphy for SLN removal in MCT. Moreover, it improves the success of lymphadenectomy, reduces surgical time, and incision length compared to an unguided technique.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"320-329"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Chemotherapy Is Associated With Prolonged Survival Time in Small-Breed Dogs Undergoing Amputation for Appendicular Osteosarcoma.","authors":"Stefano Zanardi, Silvia Sabattini, Federica Rossi, Matteo Rossanese, Paolo Buracco, Vincenzo Montinaro, Marina Aralla, Alfredo Dentini, Elisa Pizzi, Enrico Volpe, Giovanni Tremolada, Laura Marconato","doi":"10.1111/vco.13041","DOIUrl":"10.1111/vco.13041","url":null,"abstract":"<p><p>Adjuvant chemotherapy is a well-established treatment for large-breed dogs with appendicular osteosarcoma; however, it is unclear if it improves outcomes in small-breed dogs due to limited focused studies. This retrospective study aimed to investigate the oncologic outcomes of dogs weighting less than 15 kg with appendicular osteosarcoma that underwent curative resection with or without postoperative adjuvant chemotherapy. Endpoints were time to distant progression (TTDP) and overall survival (OS). Medical records from multiple institutions were reviewed, and 43 dogs were included in the analysis: 17 underwent surgery alone and 26 also received adjuvant chemotherapy. The median TTDP for all dogs was 265 days, with no significant difference between treatment groups. The median OS for all dogs was 270 days, and it was significantly different between amputated dogs (150 days) and those also receiving adjuvant chemotherapy (353 days, p = 0.002). In our cohort, osteosarcoma in small breeds behaved as aggressive as in large breeds. Adjuvant chemotherapy may prolong survival. Future randomised studies are needed to provide definitive evidence on the necessity of adjuvant chemotherapy to address metastatic spread in small-breed dogs with appendicular osteosarcoma.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"161-167"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective Study Evaluating the Outcome and Efficacy of Stereotactic Body Radiation Therapy for the Treatment of Metastatic Abdominal Lymph Nodes in Dogs With Apocrine Gland Anal Sac Adenocarcinoma.","authors":"Tiffany W Martin, Theodore Chang, Mary-Keara Boss, Brandan Janssens, Susan M LaRue","doi":"10.1111/vco.13052","DOIUrl":"10.1111/vco.13052","url":null,"abstract":"<p><p>Local treatment for dogs with regional lymph node metastasis secondary to apocrine gland anal sac adenocarcinoma (AGASACA) includes nodal extirpation or radiotherapy. Stereotactic body radiation therapy (SBRT) may provide a definitive intent treatment option for macroscopic nodal disease when surgery is declined or the disease is deemed inoperable. Twenty-five dogs receiving SBRT to the metastatic sacroiliac lymph nodes were retrospectively evaluated. Dogs were staged according to the previously published TNM staging system with 3 stage IIIa, 14 stage 3b, and 8 stage IV. The overall median survival time (MST) was 451 days and the stage did not significantly impact survival (p = 0.31). The overall median event-free survival time was 246 days. Significant positive prognostic factors included male sex, higher dose per fraction, and higher total dose (p = 0.034, 0.0035, 0.0047). Dogs receiving 6-7.5 Gy per fraction with a total dose of 30-37.5 Gy outperformed dogs receiving other protocols. Twelve dogs experienced gait changes in the hind limbs during the late radiation effects period. Resolution of hypercalcemia in 5 dogs was inconsistent and transient. The best response was complete in 21%, partial in 58%, and stable disease in 17% at a median of 100 days. Three dogs (12%) developed progression of treated lymph nodes at 157, 498, and 644 day. Eight dogs (32%) had recurrence of their primary (untreated by radiation) anal sac masses. SBRT was determined to be an effective alternative to surgical excision; however, more investigation is needed to determine the cause of gait changes in the late toxicity period.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"257-266"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genotoxic Herbicide Exposures in Golden Retrievers With and Without Multicentric Lymphoma.","authors":"Ashleigh N Tindle, Lauren M Krueger, Brenna Swafford, Erin Mani, Camille Danielson, Julia Labadie, Lauren A Trepanier","doi":"10.1111/vco.13051","DOIUrl":"10.1111/vco.13051","url":null,"abstract":"<p><p>Canine multicentric lymphoma (CML) is one of the most common malignancies in dogs. Although breed risk is important, environmental factors such as herbicides have also been implicated. The objective of this study was to determine whether genotoxic exposures to the herbicides 2,4-D and glyphosate are associated with CML, using dogs from the Golden Retriever Lifetime Study cohort. We measured urinary concentrations of glyphosate and 2,4-D in golden retrievers with CML and matched unaffected controls at two time points: at the time of diagnosis and 1 year prior to diagnosis. To assess the genotoxic potential of herbicide exposures, we used reverse dosimetry from urinary concentrations to estimate plasma concentrations. We then assessed the genotoxicity of these herbicide concentrations towards healthy canine peripheral blood mononuclear cells (PBMC's) in vitro using the CometChip assay, with and without canine liver microsomes. All dogs had detectable urinary exposures to 2,4-D (7.3-42.9 ng/mg creat) and glyphosate (0.4-80.7 ng/mg creat), with no differences between cases and controls at either time point. Both 2,4-D and glyphosate were genotoxic to canine PBMCs at concentrations of 0.10 μM and higher, with no consistent effects of canine liver microsomes on herbicide genotoxicity. No dogs reached estimated genotoxic plasma concentrations for glyphosate, but 4 of 30 golden retrievers with CML (13.3%) and 2 of 30 control dogs (6.7%) reached estimated genotoxic 2,4-D exposures (p = 0.67).</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"246-256"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerability Assessment of Orally Administered Paclitaxel With Encequidar in Dogs With Spontaneous Malignancy.","authors":"Jordan Ziegler, Jacob Cawley, Stephanie Istvan, Saya Press, Samuel Stewart, Chand Khanna, Joelle Fenger","doi":"10.1111/vco.13045","DOIUrl":"10.1111/vco.13045","url":null,"abstract":"<p><p>Paclitaxel is an antimitotic agent that targets elements of the cancer phenotype, including cell proliferation, DNA repair, and apoptosis, predicting its broad activity in a spectrum of cancers. An oral paclitaxel formulation has been developed to overcome challenges associated with parenteral administration of this drug, notably the development of Cremophor-induced acute hypersensitivity reactions, which are particularly problematic in dogs. The aim of this open-label, dose-escalating study was to evaluate the tolerability and determine the maximum tolerated dosage (MTD) and dose-limiting toxicity (DLT) of oral paclitaxel when co-administered with the P-glycoprotein pump inhibitor, encequidar, in dogs with cancer. Paclitaxel was administered as a 3-consecutive-day course starting at 90 mg/m² with encequidar weekly for 3 weeks, using escalation of 30 mg/m² increments. MTD was established using a rolling-six dose escalation study design, based on the number of dogs experiencing any DLT assessed after each dosing cycle and during a 28-day post-treatment monitoring period. Nineteen client-owned dogs were enrolled. MTD was established at 90 mg/m² and the most frequent adverse events (AEs) were gastrointestinal, followed by hematologic, with the majority being self-resolving and low grade. VCOG Grades 3 and 4 gastrointestinal toxicity, Grade 4 neutropenia, and acute kidney injury were defined as DLTs at 120 mg/m². Conclusions of this study define oral paclitaxel MTD in cancer-bearing dogs at 90 mg/m² when given with encequidar for 3 consecutive days weekly for 3 weeks. Future Phase 2 trials evaluating the therapeutic activity of oral paclitaxel at its MTD co-administered with encequidar in defined tumour histologies are warranted.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"197-204"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Half-Body Radiation Therapy Results in a Prolonged Progression-Free Interval in Canine High-Grade Lymphoma After First Remission.","authors":"Yen-Hao Erik Lai, Sarah Lyles, Mark Mitchell, Jayme Looper","doi":"10.1111/vco.13050","DOIUrl":"10.1111/vco.13050","url":null,"abstract":"<p><p>An optimal protocol of adding wide-field irradiation to multi-agent chemotherapy for dogs with lymphoma has not been established. The aim of this retrospective case-control study was to evaluate the efficacy of a protocol combining chemotherapy and half-body irradiation (HBI) for dogs with high-grade lymphoma. Dogs in the treatment group received cranial HBI 2 weeks after completing the second cycle of the multi-agent chemotherapy protocol. The radiation therapy protocol consisted of 4 Gy/fraction once per day for 2 consecutive days for the cranial half body, followed by the same protocol for the caudal half 2 weeks later. The control group only received multi-agent chemotherapy. All patients were required to have cytological confirmation of high-grade lymphoma and achieve complete remission after two cycles of multi-agent chemotherapy. Fourteen patients receiving HBI and 11 patients in the control group were included. The median progression-free interval (PFI) in the HBI group (1143 days) was significantly longer than that in the control group (316 days, p = 0.004). In the HBI group, dogs with T cell lymphoma had statistically shorter PFI (292 days) than dogs with B cell lymphoma (2127 days, p = 0.0013). The median survival time in the HBI group (1924 days) was significantly longer than that in the chemotherapy-only group (566 days, p = 0.0077). The predictive factors for longer PFI and ST were found in the patients who received HBI and chemotherapy (p = 0.0062 and 0.0252, respectively). For chemotherapy-responding patients that completed a multi-agent protocol, HBI significantly prolonged the time to tumour relapse compared with the chemotherapy-only group.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"236-245"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}